The Food and Drug Administration (FDA) updated its guidance on Tuesday to allow more wearables to fall into a general wellness category and skip the agency's expensive review process before going to ...
Reviews of Sanofi’s diabetes drug Tzield and Disc Medicine’s blood-disorder medicine bitopertin stalled Tzield pushed back after adverse event reports; bitopertin delayed two weeks amid efficacy and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results